| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
,||,||
,||,||
Departments of
*
Dermatology and
Pathology, and
Center for Molecular Medicine, University of Cologne, Cologne, Germany;
Department of Dermatology and Institute of Experimental Dermatology, University of Münster, Münster, Germany;
¶
German Research Center for Biotechnology, Braunschweig, Germany; and
||
Department of Dermatology and Allergy, University of Ulm, Ulm, Germany
In a CD18 hypomorphic polygenic PL/J mouse model, the severe reduction of CD18 (
2 integrin) to 2–16% of wild-type levels leads to the development of a psoriasiform skin disease. In this study, we analyzed the influence of reduced CD18 gene expression on T cell function, and its contribution to the pathogenesis of this disease. Both CD4+ and CD8+ T cells were significantly increased in the skin of affected CD18 hypomorphic mice. But only depletion of CD4+ T cells, and not the removal of CD8+ T cells, resulted in a complete clearance of the psoriasiform dermatitis. This indicates a central role of CD4+ T cells in the pathogenesis of this disorder, further supported by the detection of several Th1-like cytokines released predominantly by CD4+ T cells. In contrast to the CD18 hypomorphic mice, CD18 null mutants of the same strain did not develop the psoriasiform dermatitis. This is in part due to a lack of T cell emigration from dermal blood vessels, as experimental allergic contact dermatitis could be induced in CD18 hypomorphic and wild-type mice, but not in CD18 null mutants. Hence, 2–16% of CD18 gene expression is obviously sufficient for T cell emigration driving the inflammatory phenotype in CD18 hypomorphic mice. Our data suggest that the pathogenic involvement of CD4+ T cells depends on a gene dose effect with a reduced expression of the CD18 protein in PL/J mice. This murine inflammatory skin model may also have relevance for human polygenic inflammatory diseases.
This article has been cited by other articles:
|
|
 |
|
  H. Wang, T. Syrovets, D. Kess, B. Buchele, H. Hainzl, O. Lunov, J. M. Weiss, K. Scharffetter-Kochanek, and T. Simmet Targeting NF-{kappa}B with a Natural Triterpenoid Alleviates Skin Inflammation in a Mouse Model of Psoriasis J. Immunol., October 1, 2009; 183(7): 4755 - 4763. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Y. Chang, F. Zhao, X. He, H. Ren, S. Braselmann, V. Taylor, J. Wicks, D. G. Payan, E. B. Grossbard, P. R. Pine, et al. JAK3 Inhibition Significantly Attenuates Psoriasiform Skin Inflammation in CD18 Mutant PL/J Mice J. Immunol., August 1, 2009; 183(3): 2183 - 2192. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Danilenko Review Paper: Preclinical Models of Psoriasis Vet. Pathol., July 1, 2008; 45(4): 563 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wang, D. Kess, A.-K. B. Lindqvist, T. Peters, A. Sindrilaru, M. Wlaschek, R. Blakytny, R. Holmdahl, and K. Scharffetter-Kochanek A 9-Centimorgan Interval of Chromosome 10 Controls the T Cell-Dependent Psoriasiform Skin Disease and Arthritis in a Murine Psoriasis Model J. Immunol., April 15, 2008; 180(8): 5520 - 5529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liang, C. Liu, J. Y. Djeu, B. Zhong, T. Peters, K. Scharffetter-Kochanek, C. Anasetti, and X.-Z. Yu 2 integrins separate graft-versus-host disease and graft-versus-leukemia effects Blood, January 15, 2008; 111(2): 954 - 962. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Ostanin, K. L. Furr, K. P. Pavlick, L. Gray, C. G. Kevil, D. Shukla, D. D'Souza, J. M. Hoffman, and M. B. Grisham T cell-associated CD18 but not CD62L, ICAM-1, or PSGL-1 is required for the induction of chronic colitis Am J Physiol Gastrointest Liver Physiol, June 1, 2007; 292(6): G1706 - G1714. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Kess, A.-K. B. Lindqvist, T. Peters, H. Wang, J. Zamek, R. Nischt, K. W. Broman, R. Blakytny, T. Krieg, R. Holmdahl, et al. Identification of Susceptibility Loci for Skin Disease in a Murine Psoriasis Model J. Immunol., October 1, 2006; 177(7): 4612 - 4619. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
